Tech Company Financing Transactions
Ceregene Funding Round
On 6/21/2007, Ceregene raised $28.1 million in Series C funding from Investor Growth Capital.
Transaction Overview
Company Name
Announced On
6/21/2007
Transaction Type
Venture Equity
Amount
$28,100,000
Round
Series C
Investors
Investor Growth Capital (Lead Investor)
Proceeds Purpose
Company CEO Jeffrey Sotrove said the round "provides the funding we currently need to advance CERE-120 toward commercialization."
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
9381 Judicial Dr. 130
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Using gene therapy delivery systems, Ceregene's primary focus is the discovery and development of novel genetic therapeutics for the treatment of neurological disorders. Ceregene aims to be the leader in the field of Central Nervous System (CNS) disease treatment using molecular medicine, an area of great unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Ostrove
Chief Scientific Officer
Raymond Bartus
Controller
Carolyn Bonebright
Browse more venture capital transactions:
Prev: 6/21/2007: Danal venture capital transaction
Next: 6/21/2007: CSA Medical venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs